TREATMENT ADHERENCE TO CONVENTIONAL AND BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：1
|
作者：
Feldman, C. H. [1 ]
Lii, J. [1 ]
Gopalakrishnan, C. [1 ]
Franklin, J. M. [1 ]
Kim, S. C. [1 ]
机构：
[1] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.5544
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0664
引用
收藏
页码：526 / 526
页数：1
相关论文
共 50 条
  • [31] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD) IN THE TREATMENT OF PATIENTS WITH RHEUMATOID-ARTHRITIS
    HALBERG, P
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1986, : 55 - 57
  • [32] DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
    Wang, Susan Siyu
    Lewis, Myles J.
    Pitzalis, Costantino
    BIOMEDICINES, 2023, 11 (07)
  • [33] Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate
    Koyama, Yoshinobu
    Shiraishi, Hirokazu
    Ohta, Toshiyuki
    Uchino, Ayumi
    MODERN RHEUMATOLOGY, 2012, 22 (01) : 100 - 108
  • [34] Defining response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis
    Hider, SL
    Bruce, IN
    Silman, AJ
    Symmons, DPM
    JOURNAL OF RHEUMATOLOGY, 2005, 32 (01) : 6 - 10
  • [35] ADHERENCE TO DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A QUALITATIVE STUDY IN TWO ETHNIC GROUPS
    Kumar, K.
    Raza, K.
    Gill, P.
    Greenfield, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 358 - 358
  • [36] Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Machado, Marina
    Moura, Cristiano
    Behlouli, Hassan
    Curtis, Jeffrey
    Bernatsky, Sasha
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 937 - 938
  • [37] COMPARATIVE EFFECTIVENESS OF TOFACITINIB, BIOLOGIC DRUGS AND TRADITIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Moura, C. S.
    Machado, M. A.
    Behlouli, H.
    Curtis, J. R.
    Abrahamowicz, M.
    Bernatsky, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 825 - 826
  • [38] Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Machado, Marina
    Moura, Cristiano S.
    Behlouli, Hassan
    Curtis, Jeffiey R.
    Bernatsky, Sasha
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [39] Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
    Yinzhu Jin
    Rishi J. Desai
    Jun Liu
    Nam-Kyong Choi
    Seoyoung C. Kim
    Arthritis Research & Therapy, 19
  • [40] German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs
    Katinka Albrecht
    Klaus Krüger
    Jürgen Wollenhaupt
    Rieke Alten
    Marina Backhaus
    Christoph Baerwald
    Wolfgang Bolten
    Jürgen Braun
    Harald Burkhardt
    Gerd R. Burmester
    Markus Gaubitz
    Angela Gause
    Erika Gromnica-Ihle
    Herbert Kellner
    Jens Kuipers
    Andreas Krause
    Hans-Martin Lorenz
    Bernhard Manger
    Hubert Nüßlein
    Hans-Georg Pott
    Andrea Rubbert-Roth
    Matthias Schneider
    Christof Specker
    Hendrik Schulze-Koops
    Hans-Peter Tony
    Siegfried Wassenberg
    Ulf Müller-Ladner
    Rheumatology International, 2014, 34 : 1 - 9
12345